Advanced Wound Healing Dressings with Active Indicatior of Bacterial Infection

每年，英国国民健康保险制度在伤口护理上的花费为80亿英镑。在这一预算中，三分之二，即56亿GB用于治疗慢性和复杂的伤口，如静脉性腿部溃疡和无法愈合的糖尿病伤口。全科医生、足科医生、社区和医院工作人员每天都会对患者的复发需求做出反应，这些患者的慢性伤口需要工作人员的时间、药物和先进的伤口敷料。尽管投入了时间和精力，但超过一半的患者需要12个月以上的时间才能痊愈。在此期间，痛苦的着装更换频繁，感染是持续的风险，心理伤害和社会孤立是常见的。更糟糕的是，在糖尿病患者等高危人群中，高达五分之一的患者需要截肢；截肢后，5年死亡率为39%，有些人群的死亡率高达57%。面对这一黯淡的现实，市场上已经出现了一些“高级敷料”。然而，只有不到10%的患者因为成本高和临床证据不足而接受了先进的敷料。因此，大多数应用于慢性伤口的敷料在50年或更长时间内没有显著变化。科林生物技术公司正在开发一种非接触式伤口敷料系统，以改变慢性和复杂伤口的治疗方式。使用我们的手持敷贴器，医疗保健专业人员可以在患者家中、门诊或其他地方直接使用先进的纳米纤维材料，而无需与患者接触。通过将科林生物科技独特的应用方法、材料结构和选定的指示性化合物相结合，可以解决伤口评估中当前的挑战，如感染的早期识别。科林生物科技的伤口敷料材料比其他生产的先进敷料更实惠：在美国，其他纳米纤维电纺敷料的成本可达数百至数千美元，而用科林敷料器生产的敷料成本可能低至GB 50\。创新英国基金允许开发和研究具有先进能力的敷料，比目前的敷料系统和诊断方法更早地突出感染。这一额外的功能将使科林的伤口敷料不仅能立即减轻患者的疼痛和痛苦，还能防止严重感染的连锁反应。科林生物技术公司的目标是提供伤口治疗的新范式，以及先进敷料的产品线，通过降低医疗成本和改善结果，使患者、护理人员和更广泛的公众受益。

Every year, the NHS spends £8 billion on wound care. Of this budget, two thirds, or £5.6 billion is spent on the treatment of chronic and complex wounds such as venous leg ulcers, and non-healing diabetic wounds. GP's, podiatrists, community, and hospital staff all respond daily to the recurrent needs of patients whose chronic wounds require staff time, drugs, and advanced wound dressings.Despite this investment of time and effort, over half will take more than 12 months to heal. During this time painful dressing changes are frequent, infection is a constant risk, and psychological damage and social isolation is common. Worse, in high-risk groups such as diabetics, up to 1 in 5 will require amputation; and, post-amputation, the 5 year mortality rate is 39%, and for some groups is as high as 57%.In the face of this bleak reality, a number of 'advanced dressings' have come to the market. However, less than 10% of patients receive 'advanced dressings' due to their cost, and frequently poor clinical evidence base. For this reason, the majority of dressings applied to chronic wounds have not changed significantly in 50 years or more.Corryn Biotechnologies is developing a non-contact wound dressing system to transform the way chronic and complex wounds are treated. Using our handheld applicator a healthcare professional can apply advanced nanofibrous materials without contact to the patient, directly in their own home, an outpatient clinic, or elsewhere. Through the combination of Corryn Biotechnologies' unique application method, material architecture, and selected indicative compounds - current challenges in wound assessment, such as the early identification of infection, can be addressed.Corryn Biotechnologies' wound dressing materials are substantially more affordable than other advanced dressings produced: other nanofibrous electrospun dressings in the United States can cost hundreds to thousands of dollars, while a dressing produced with Corryn's applicator may cost as little as £50\. Innovate UK funding allows development and research of dressings with advanced capabilities to highlight infections far earlier that current dressing systems and diagnostic methods. This additional functionality will allow Corryn's wound dressings to function not only to reduce pain and suffering to patients immediately, but prevent the knock-on effects of serious infection. Corryn Biotechnologies aims to deliver a new paradigm of wound treatment, and a product pipeline of advanced dressings to benefit patients, caregivers, and the wider public through reduced healthcare costs and improved outcomes.